Abstract
A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Current Drug Discovery Technologies
Title: Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Volume: 4 Issue: 3
Author(s): Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson, David Sugden, Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson and David Sugden
Affiliation:
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Abstract: A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Export Options
About this article
Cite this article as:
Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn, Sugden David, Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn and Sugden David, Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics, Current Drug Discovery Technologies 2007; 4 (3) . https://dx.doi.org/10.2174/157016307782109715
DOI https://dx.doi.org/10.2174/157016307782109715 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly
Current Alzheimer Research Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research The Physiological Characteristics and Transcytosis Mechanisms of the Blood-Brain Barrier (BBB)
Current Pharmaceutical Biotechnology Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Tyrosine Hydroxylase Gene: Another Piece of the Genetic Puzzle of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Neuroprotective and Preventative Effects of Molecular Hydrogen
Current Pharmaceutical Design Stress and Vulnerability Due to the Care Task: An Observational Study on Older Caregivers
Current Psychopharmacology Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research Alzheimer’s Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review
Current Psychiatry Research and Reviews Editorial: View of Excellent ROAD from the CAR
Current Alzheimer Research Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Editorial (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference)
Current Alzheimer Research Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Will Diverse Tat Interactions Lead to Novel Antiretroviral Drug Targets?
Current Drug Targets Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine